Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2024 Earnings Call Transcript

Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2024 Earnings Call Transcript November 10, 2023

Operator: Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation FY 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks there will be a question-and-answer session. [Operator Instructions]. I would now like to turn the conference over to Dick Johnson, Chief Financial Officer. Please go ahead.

A – Richard G. Johnson: Well, thank you Regina and good morning to everyone, and welcome to Phibro’s earnings call for our fiscal first quarter ended September 30th. My name is Dick Johnson, I’m the Chief Financial Officer of Phibro Animal Health Corporation. I’m joined today on the call by Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer; and also by Daniel Bendheim, Director and Executive Vice President of Corporate Strategy. Today, we’ll cover financial performance for our first quarter and provide an update on our financial guidance for our full fiscal year ending June 2024. At the conclusion of our opening remarks, we’ll open the lines for your questions. I’d like to remind you that we’re providing a simultaneous webcast of this call on our website, pahc.com and also on the Investors section of our website.

Later today, you will find copies of the earnings press release and the first quarter Form 10-Q filed with the SEC yesterday as well as the slides and transcripts from our presentation this morning. Turning to Slide 2, just the standard disclaimers. Our remarks today will include forward-looking statements and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements section in our earnings press release. Our remarks include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or U.S. GAAP. I refer you to the non-GAAP financial information section in our earnings press release for a discussion of these measures.

Reconciliations of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items; unusual, nonoperational or nonrecurring items, including stock-based compensation; other income or expenses separately reported in the consolidated statement of operations, primarily foreign currency gains and losses; and the income tax effects related to any of those pretax adjustments plus any unusual or nonrecurring income tax items. Now let me introduce our Chairman, President and Chief Executive Officer, Jack Bendheim, to share his perspective on Phibro’s first quarter financial performance and the outlook for our fiscal year 2024.

Jack?

Jack C. Bendheim: Thank you, Dick. Good morning, everyone and thank you for joining us today. Our first quarter had some strong positives despite the overall disappointing results. Our core animal health business grew sales at a healthy 4% and I was especially pleased to see that some of the measures we have taken to counteract margin erosion helped the Animal Health EBITDA grow at an even faster rate of 6%. We saw growth across all three product categories in Animal Health, led by 14% growth in vaccines. We are seeing increased uptake of our vaccines across multiple regions, but especially in South America where we had launched several new commercial vaccines, as well as has opened a new autogenous vaccine facility in Brazil.

We are continuing to invest behind our successes. We’re looking to introduce additional vaccines in the Americas and have just recorded our first sales of a new line of nutritional specialty products for U.S. poultry producers. We see vaccines and nutritional specialties as double-digit annual opportunities for the short and medium term, and we are making the necessary investments to enable us to achieve our targets. We are also continuing to support our other initiatives such as companion animal. But considering the challenging macro environment we are targeting ways to curtail or delay some of the spend. As mentioned, we are in a challenging macro environment. Our Mineral Nutritional business has seen revenue drop and margins drop even more as we have recently been on the wrong side of commodity price movements and some of the inventory positions.

While we anticipate our margins returning to some historical levels as we progress through the fiscal year, volumes could take longer to recover. Similarly, we see weaknesses in some of the other end markets, including dairy in the U.S. and China and our feedlot businesses in Latin America. Finally, the horrific terrorist attacks in Israel a month ago and the subsequent war have increased the costs relating to our operations in Israel. We have confidence in our ability to meet our supply commitments to customers. For all these reasons, we have decided to lower our guidance for the remainder of this fiscal year, as Dick will go into in greater detail at the end of his presentation. Before I hand it back to Dick, I want to touch on the FDA’s most recent action relating to Mecadox.

The FDA has been targeting Mecadox for close to a decade. Mecadox is a very important product for swine producers to help keep baby piglets healthy during the critical early period of their lives. It’s been safely sold in the United States for over 50 years and continues to be available and to be used. We will continue to support this product and defend our customers’ ability to use it. We are extremely confident in its safety and efficacy. With that, I look forward to hearing your questions following Dick’s review of our financials.

A – Richard G. Johnson: Thanks, Jack. Well, let me start with the consolidated financial performance on Slide 4, then move on to segment-level performance and other factors, and I’ll conclude with a review of our updated financial guidance. Our consolidated net sales for the quarter ending September were about $231 million, reflecting a decrease of $1 million or 1% compared with the same quarter a year ago. As Jack mentioned, the Animal Health segment saw a nice increase, while both Mineral Nutrition and Performance Products decreased from the year earlier. GAAP-based net income and diluted earnings per share decreased, driven in part by higher SG&A expenses and notably by a $10.4 million charge for pension settlement cost. We also saw increased interest expense due primarily to higher rates, some increased foreign exchange losses, all of which were partially offset by reduced income tax provision.

Our first quarter adjusted EBITDA was $18.7 million, that was a decrease of $3.5 million. Within that, Animal Health increased $1.5 million due to sales growth and favorable gross margins, which was partially offset by higher spending and SG&A. Mineral Nutrition decreased $2.4 million at the EBITDA line due to lower sales and higher costs. Performance Products dropped about $1 million compared to last year at the EBITDA line due to lower sales and driving in that — driving gross profit down. And finally, corporate expenses increased $1.6 million year-over-year due to increased strategic investments, some of which was timing and also higher employee-related costs. At the adjusted net income and adjusted diluted EPS lines, we saw adjusted EPS of $0.14, that was down a third from a year earlier, driven by primarily the higher G&A — SG&A expenses.

Just as a reminder, the large one-off pension charge was — is not included in adjusted net income, but driven by other SG&A spending and higher interest expense, again, partially offset by reduced income taxes. So now if we move to segment-level financial performance, our first quarter performance of our largest segment, Animal Health. Animal Health segment posted $160 million of sales for the quarter, that was an increase of close to $6 million or 4%. And within that sales increase, we saw, as Jack pointed out, a better than $3 million increase or 14% growth in vaccine net sales. The increase was driven primarily by poultry product introductions in Latin America and also growth in the U.S. swine sector, but there was some offset, a partial offset due to timing of deliveries in other international regions.

In nutritional specialties, we saw a growth of about $1 million or 3%. And there it was driven by increased volumes in poultry products, primarily in the U.S. domestic market. And finally, MFA is another, increased about $1 million or 1%, and that increase was driven by increased sales of processing aids used in the ethanol fermentation industry. In terms of profitability for this segment, Animal Health adjusted EBITDA was $28.5 million, up 6% from the same quarter a year earlier and a 30 basis point improvement in adjusted EBITDA margin due to the improved gross profit in the segment. Moving on to first quarter financial performance in our other business segments on Slide 6 and starting with Mineral Nutrition. Net sales were $56 million, down about $3.5 million or 6% versus the same quarter last year.

There was declines — the sales declined due to lower average selling prices and reduced volumes due to a drop in demand and Mineral Nutrition adjusted EBITDA dropped even more strongly at $2 million. It was a 46% decline year-on-year, driven by the sales decline and higher costs. Looking at Performance Products, net sales were about $15 million for the quarter, down about $3 million or 8% [ph]. And this was driven primarily as lower demand for ingredients used in personal care products, and that reduced sales drove a decline in adjusted EBITDA of about $1.4 million, a large percentage decline on a relatively small base. And corporate expenses were up 13%, driven by strategic investments and employee-related costs. Turning to key capitalization-related metrics, our free cash flow for the 12-month period ending September was a positive $4 million.

That’s first time in some time that we’ve seen a trailing 12-month positive free cash flow. So that’s good news and reflects a lot of work and progress we’re making in managing our working capital and our cash flows. And just it was comprised overall of, over that 12-month period, of $40 million from operating activities, less $36 million of capital expenditures. We ended the quarter with a gross leverage ratio of 4.4 times. That’s a simple math of $484 million of total debt divided by $109 million of trailing adjusted EBITDA. Looking at the dividends, consistent with our history, we’ve paid a quarterly dividend during the quarter of $0.12 a share, which is about $4.9 million in the aggregate. And as a reminder, $300 million of our debt is not exposed to rising interest rates because we fixed the variable portion of our interest rate to a fixed rate of 61 basis points plus the margin adder.

The remainder of our debt is subject to floating interest rates, which are now determined by SOFR, which is the replacement for LIBOR. We also are seeing some partial offset from higher earnings, interest income earned on our short-term investments. And now let’s look at our updated guidance. So if we look at those boxes on the right-hand side, we show you the new updated guidance. Just call out a couple of lines. Sales now expected to be between $980 million and $1,020 million; and adjusted EBITDA, 106 — between $106 million and $112 million. And you see the other numbers that are driven by those two key metrics. The updated guidance reflects reduced expectations for the fiscal year compared with our previous guidance. We see difficult fundamentals in certain parts of our business, including international beef, feedlots, the U.S. and China dairy sectors, and the pace of recovery in the Mineral Nutrition and Performance Products segments, plus the cost of manufacturing disruptions and inefficiencies due to the current conflict in Israel.

I would note that we expect our December quarter to be roughly similar to or less than last year, reflecting some of the issues described above. So in closing, this is a challenging environment from various perspectives, but we remain confident in the demand for our products around the world and the longer-term opportunities ahead of us. And with that, operator, if you would please open the line for questions. Thank you.

See also 12 Best Blue Chip Stocks To Buy Today and 10 Best Auto Stocks To Buy.

Q&A Session

Operator: [Operator Instructions]. Our first question will come from the line of Balaji Prasad with Barclays. Please go ahead.

Unidentified Analyst: Hi, good morning everyone. This is Mikaela on for Balaji. Can you hear me.

Jack C. Bendheim: Yes.

Unidentified Analyst: Great. Just wanted to dig in a bit more around the FDA’s recent notice for Carbadox and the potential implications for Mecadox. As you mentioned, it seems you provided a great deal of safety data to the FDA in prior instances. So just wondering what your next steps here will look like? Thanks.

Jack C. Bendheim: Can’t fully go through what our next steps are. But as I’ve said earlier and I think we said in our press release, this product has been on the market for 50 years. It’s safe and an effective product and we have sort of been badgering the FDA. They don’t like this product because it has some carcinogenic products in it. But by law, as long as there’s no leftover carcinogenic products in the meat, it’s safe to use. And we’ve proven that, and we’ve seen some of that over, and we’ve tested it up on the FDA with us over these last 50 years. So there might be some mindset changes in the FDA, but this product is used by most of the hog producers in the United States. And again, it’s safe and effective.

Unidentified Analyst: Great, thanks. And just one follow-up, can you just remind us of how Rejensa has been tracking? Thanks.

Daniel M. Bendheim: I’ll take that. This is Donny. So Rejensa continues on sales out to grow nicely. It’s not immune to the kind of slowdown we’ve seen in the vet channel throughout the industry. So the pace has slowed a little bit, but overall, we continue to be happy with its growth and it’s getting planned.

Unidentified Analyst: Thanks so much.

Operator: Your next question comes from the line of Michael Ryskin with Bank of America. Please go ahead.

Michael Ryskin: Hey guys, thanks for taking the questions. And Dick, welcome back. It’s been a while. I want to ask first on some of your comments regarding further outlook for fiscal year 2024. You specifically called out OUS, international beef feedlots. Just wondering if you could expand a little bit on what’s going on there. We often hear about U.S. beef feedlots and herd contraction and some of the pressures there, but not as much discussion as what’s happening internationally, so any color could be really helpful?

Jack C. Bendheim: I mean the color is around our business in Latin America, where — which is generally it’s the higher cost of grain, which has put pressure and turned some of these businesses and some of the production of beef into loss businesses. So we’ve seen drop in volume and fewer cows on the feedlot, which translates for us into fewer products sold. We see corn prices starting to drop. They were in the 7s, and now they’re down into the 6s. USDA is projecting higher — projecting higher production of corn in the United States. So the prices have dropped further, and we see that business should turn around. And that’s basically been the driver.

Michael Ryskin: Okay. So it sounds like it’s primarily macro-driven and tied to input costs, especially feed costs and hopefully, that will be relatively quick to turn around, is that the right interpretation?

Jack C. Bendheim: Exactly. I mean that’s what we’re seeing, and that’s what we’re seeing also in the dairy business.

Michael Ryskin: Okay, great. No, dairy was actually going to be another one of my questions. So then if I could ask on the vaccine strength. I mean that’s been a really good business for you for a while now, but you really emphasized that this quarter that vaccines, especially in LatAm, was doing really well. Is that any particular product introduction that should be called out or is it a broad portfolio effect, I know you guys did an acquisition a couple of years ago where you brought in some novel vaccine technology. Is that what we’re seeing the benefits of, if you could just add it to the vaccine strength, that would be great?